We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not that old chestnut ahfam! Of course we are not in negotiations, did you not see the price of our most recent placing?
Brighty, who's to say we are not in negoatiations already. We know how complex Tyk2 is we have cance, auto-immune and many other indications it can be used for- so the deal could be complicated and putting a value on all that is difficult as we do not know how the risperitory market will pan out over the coming years. The only indications we have is the celgene/bms deal size and the share-price movements of hemo, avacta and most notably novacyt. In my opinion if someone is looking to licence the value being negotiated has to be well over the £800m Tim mentioned all those years ago since now with covid19 it will no doubt have risen- so negotiations could drag on for a while.
A Hemo x15 style gain in the sp is not to be sniffed at. Lets hope Sareum can do the same for us.
Potnak and RMM, I'm an investor not a day trader and have had numerous opportunities to sell Sareum at a respectable profit over the years but as, like you, I so believe in this company I have been holding out for a much higher price. Starting to look a bit silly now sadly as I watch AVCT, HEMO, ODX, NCYT, SNG etc etc all make significant gains in the last 6 months whilst Sareum with all its "promise" (and "promises") does nothing apart from issue the odd tweet and dilute further without any news of what the dickens they have been doing for the last year or so. I am expecting a return on my "investment", that is my point and if Hemo can strike a deal with Eli Lilly it is a fair question to ask why Sareum have not? Other companies appear to be much more hungrier and on the ball than we are. The Bio Trinity presentation and follow up online interview he did with all his vague answers was a disgrace. I hope that Tim is going to pull a rabbit out of the hat very soon. It's about time. Brighty
I think Hemo is totally correct, I can't see any investor or trader complaining about making 15x
Whatever you want to call a person is all semantics.
Sareums outstanding number of issued shares is up massively from 2011 due to incessant dilution. Anyone hoping for 15x here now has to understand the dynamics of what that will propel the market cap to. I just don't think it's realistic to expect another 2011 I'm afraid. Besides, how many serious investors and investing publications have "heard it all before" from Tim? His words don't the carry weight they once commanded. There is a limit to unfulfilled time horizons, excuses and shareholders dilutions.
Time is running out for Sareum. No wonder Millennium let these guys go with their discoveries!
Think you are mixing up trading and investing,Brighty.
Hemo is for traders some have done very well, many have not. They have raised twice this year and are now tied to a deal with no risk to Lilly. If they don't come us with anything soon, the house of cards will fall. In the meantime, the traders will do very well out if it. Hemo is the epitome of AIM casino.
Brighty - let me clarify why I would be so upset if SAR replicated the HEMO deal with Lilly. Lilly come to SAR and say they would like to offer Gemcitibane for further trials with SRA737. They will supply Gemcitibane for free. There are no upfront payments or even any milestones. In 2 years time when the trials have been completed, at SAR's expense, Lilly have the option to licence. I really can't see how that would move SAR's SP any way other than down - possible jam in 2 years? I can hear the screaming hit record levels! I don't for one moment think this is what Tim would do, even the Aurora deal proves we can get money out of what we thought was a dead product. What would please me considerably is that 737 gets on-licenced, milestones are paid (possibly even renegotiated higher as we now have data) and the SP hits 3p overnight and stays there. We then have a bedrock for what's to come with TYK2. I posted a couple of years ago that a buyout price for SAR was probably in the region of 16p. However, unlike Hemo we have over 3bn shares in circulation compared to their 434m with a Market Cap of £38m. Hemo peaked in April and even with yesterday's revelation they are not even close to matching the April spike. We're all here to make money but to catch a spike you have to sit here all day with your trigger finger poised and hope that you can actually sell when the spike comes. Alternatively SAR could do a deal that re-rates and allows LTH's to exit profitably over an extended period of time. It's just my opinion. I'm not being critical if all you want is a spike but at this point in time my view is that a Hemo type deal would be to sell us short and undermine what's to come from TYK2.All IMO GLA
Gob smacked by your response RMM. You might be very very angry if this occurred but Hemo’s share price has gone from 0.95p to 15p. As an investor that is what I am interested in. i.e. seeing a return on my investment not watching our ceo miss every trick in the book to capitalise on our best in class science. If the Sareum share price went from 0.95 to 15p that would be a result and I wouldn’t be angry I would be delighted. Brighty
We thought it would be a blood bath last year but they sweet talked their way out of it and we're no further on in terms of the much trumpeted increase in shareholder value, or anything else for that matter. A veil of torpor seems to have settled over Pampisford which seems destined to remain ad infinitum under the present BoD.
BoD? Bunch of Dinosaurs
We been dearing about this grant and license for months now but the bod are fast asleep.
Please do not disturb.
Brighty - from what I can see Lilly have simply offered up a 'supply arrangement' and the Hemo SP has jumped on the fact its Lilly and what it might mean. However, Lilly have not put up any cash from what I can see and have an 'option' to take a licence only if the research goes anywhere. All the risk sits with Hemo. If SAR did something similar I would be very, very upset.
You would hope that with a wage bill of around £400K Per annum, they would be working their little cotton socks off to find a deal .... let’s hope they have success before the AGM ... else it may become a blood bath
We have substantially more than Hemo and the Pharma industry knows it. It's only a matter of time and when it comes not if but when the share-price movement will be astronomical, I can assure you of that- the AIM crowd love to pump things to the high heaven so to speak we saw it in 2011 with the 10 out 10 for Aurora with remarks of 'cancer cure', 'this is going to £1' etc. The difference this time is we are in a worldwide pandemic and out our Tyk2 has no mtd and tox issues and is being investigated for lupus by US Army, muscle re-growth by the Chinese army, whopped Pfizer's tofa in RA and we also have a cancer molecule and indications against respiritory illnesses like covid which will be with us for 2-3yrs+ and the medical community knows it and have raved about it. So just a matter of time.
"Hemogenyx Pharmaceuticals will grant Lilly a research license for anything jointly developed under the AgreementIsnt".
Question: Isn't this what we hired Stephen Parker and the NED's to do on our behalf? Why haven't we signed a "Biological Investigation and Material Supply Agreement" with Eli Lilly or ANother. Hemo have stolen a march on us. This could and should have been Sareum. How many more times are we going to be late to the party? Brighty
Lol .. let’s hope we can all do screams of joy one day !
Arumel - you'll be deafened by the cocophony of many others sreaming with you!!
BasilAlderman, that small glimmer of hope is what has been keeping me here for 10 years + ... we allegedly have 'best in class' compounds, yet others who seemingly have less manage to strike agreements with the big boys .. might just go into a corner and scream !
I guess, Arumel, that the glimmer of light that you can take from the Hemo experience is that their share price was not dissimilar to our own at 0.95p a few months back. We can only hope that we undergo a similar 1p to 15p rise when Sareum issues news of a partnership / licencing deal. It is certainly most frustrating just waiting and waiting.
Autoimmune seems to be a hot topic .. unfortunately I don’t see the SAR team capitalising on any of this ... 4 months on and they still filling out the forms for COVID grant applications .. don’t know whether to laugh or cry !
Come on Tim and the Sar team, this is hitting the news today re Hemo (see below Eli Lilly news just announced) moving forward with a partnership. We really need to hear from Sareum about how things are progressing.
Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engaged in the research, development, manufacture and marketing of human pharmaceutical and veterinary products.
Under the Agreement, Lilly will supply the Company with certain biological materials and related confidential information in order for Company to perform research and development activities aimed at the discovery and validation of novel materials ("Materials") to be used for the treatment of systemic lupus erythematosus ("Lupus") and possibly other autoimmune diseases.